Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Don't stint on DMP (disease management programme) quality, warns German minister:

This article was originally published in Clinica

Executive Summary

The successful introduction of the disease management programmes (DMPs) is a test for the self-governing bodies of the German health service, says Klaus Kirchner, chairman of the health committee of the German lower house (Bundestag). Mr Kirchner said last week in Berlin, that "under no circumstances" should doctors associations or sickness funds attempt to introduce a diluted version of the DMPs, which are aimed at offering optimal treatment to the chronically ill. "The aim of the DMPs should be to provide a high standard of medical care with better quality and security for the patient and doctor. Any attempt to block this quality improvement is unacceptable," he said. Mr Kirchner added that, if any party failed to comply with the requirements of such programmes, they would be responsible for future demands for change to the health system.

You may also be interested in...

US COVID-19 Fraud: Latest Chloride Dioxide Products Linked To Claims Are Oral Rinses

Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.

CMS Removes Some Stark Law ‘Bureaucratic Barriers’ In Final Rule

The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.

Alzheimer’s Drug & Dermatitis JAK inhibitor Among New EU Filings

Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts